Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
Gene Ther ; 18(9): 849-56, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21451576

ABSTRACT

Sleeping Beauty (SB3) transposon and transposase constitute a DNA plasmid system used for therapeutic human cell genetic engineering. Here we report a comparison of SB100X, a newly developed hyperactive SB transposase, to a previous generation SB11 transposase to achieve stable expression of a CD19-specific chimeric antigen receptor (CAR3) in primary human T cells. The electro-transfer of SB100X expressed from a DNA plasmid or as an introduced mRNA species had superior transposase activity in T cells based on the measurement of excision circles released after transposition and emergence of CAR expression on T cells selectively propagated upon CD19+ artificial antigen-presenting cells. Given that T cells modified with SB100X and SB11 integrate on average one copy of the CAR transposon in each T-cell genome, the improved transposition mediated by SB100X apparently leads to an augmented founder effect of electroporated T cells with durable integration of CAR. In aggregate, SB100X improves SB transposition in primary human T cells and can be titrated with an SB transposon plasmid to improve the generation of CD19-specific CAR+ T cells.


Subject(s)
Antigens, CD19/metabolism , Gene Transfer Techniques , Receptors, Antigen/metabolism , T-Lymphocytes/metabolism , Transposases/genetics , Cell Line, Tumor , Cytotoxicity, Immunologic , Electroporation , Humans , Neoplasms/immunology , RNA, Messenger , Receptors, Antigen/genetics
4.
Cytotherapy ; 7(2): 116-25, 2005.
Article in English | MEDLINE | ID: mdl-16047416

ABSTRACT

Poor immune reconstitution after haplo-identical stem cell transplantation results in high mortality from viral infections and relapse. One approach to overcome this problem is to deplete alloreactive cells selectively by deleting T cells activated by recipient stimulators, using an immunotoxin directed against the activation marker CD25. However, the degree of depletion of alloreactive cells is variable following stimulation with recipient PBMC, and this can result in GvHD. We have shown that using recipient EBV-transformed LCL as stimulators to activate donor alloreactive T cells results in more consistent depletion of in vitro alloreactivity while preserving T-cell responses to viral and potential myeloid tumor Ag. Based on these data, we have embarked on a phase I clinical dose escalation study of add-back of allo-LCL-depleted donor T cells in the haplo-identical setting, to determine if the allodepletion we achieve to allow infusion of sufficient T cells to restore useful antiviral/anti-leukemic responses without causing GvHD. Fifteen patients have so far been treated. The incidence of significant acute or chronic GvHD has been low (2/15), as has mortality from infection (1/15). Preliminary data show accelerated immune reconstitution in dose level 2 patients. Infused allodepleted donor T cells appear able to expand significantly in the face of viral reactivations, and doses as low as 3 x 10(5)/kg may be sufficient to confer useful antiviral immunity in this setting. At a median follow-up of 19.5 months, nine of 15 patients are alive and disease-free. Five patients have relapsed, all of whom have died.


Subject(s)
Lymphocyte Depletion/methods , Recovery of Function , Stem Cell Transplantation , T-Lymphocytes/transplantation , Clinical Trials, Phase I as Topic , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/prevention & control , Graft vs Leukemia Effect/immunology , Haplotypes/immunology , Humans , Multicenter Studies as Topic , Recovery of Function/immunology , T-Lymphocytes/immunology , Transplantation, Homologous
5.
FASEB J ; 13(14): 2071-82, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10544190

ABSTRACT

Studies of T lymphocyte activation with mitogenic lectins during spaceflight have shown a dramatic inhibition of activation as measured by DNA synthesis at 72 h, but the mechanism of this inhibition is unknown. We have investigated the progression of cellular events during the first 24 h of activation using both spaceflight microgravity culture and a ground-based model system that relies on the low shear culture environment of a rotating clinostat (clinorotation). Stimulation of human peripheral blood mononuclear cells (PBMCs) with soluble anti-CD3 (Leu4) in clinorotation and in microgravity culture shows a dramatic reduction in surface expression of the receptor for IL-2 (CD25) and CD69. An absence of bulk RNA synthesis in clinorotation indicates that stimulation with soluble Leu4 does not induce transition of T cells from G0 to the G1 stage of the cell cycle. However, internalization of the TCR by T cells and normal levels of IL-1 synthesis by monocytes indicate that intercellular interactions that are required for activation occur during clinorotation. Complementation of TCR-mediated signaling by phorbol ester restores the ability of PBMCs to express CD25 in clinorotation, indicating that a PKC-associated pathway may be compromised under these conditions. Bypassing the TCR by direct activation of intracellular pathways with a combination of phorbol ester and calcium ionophore in clinorotation resulted in full expression of CD25; however, only partial expression of CD25 occurred in microgravity culture. Though stimulation of purified T cells with Bead-Leu4 in microgravity culture resulted in the engagement and internalization of the TCR, the cells still failed to express CD25. When T cells were stimulated with Bead-Leu4 in microgravity culture, they were able to partially express CD69, a receptor that is constitutively stored in intracellular pools and can be expressed in the absence of new gene expression. Our results suggest that the inhibition of T cell proliferative response in microgravity culture is a result of alterations in signaling events within the first few hours of activation, which are required for the expression of important regulatory molecules.


Subject(s)
Lymphocyte Activation , Space Flight , T-Lymphocytes/immunology , Antigens, CD/analysis , Antigens, Differentiation, T-Lymphocyte/analysis , Cell Cycle , DNA/biosynthesis , Humans , Interleukin-1/biosynthesis , Lectins, C-Type , Monocytes/metabolism , Protein Kinase C/physiology , Receptors, Antigen, T-Cell/physiology , Receptors, Interleukin-2/analysis , Rotation , Tetradecanoylphorbol Acetate/pharmacology
6.
Br J Haematol ; 69(1): 71-80, 1988 May.
Article in English | MEDLINE | ID: mdl-3382600

ABSTRACT

In whole blood from splenectomized subjects (n = 20), red cells showed a significant increase of mean surface area (MSA), mean cell volume (MCV), MSA/MCV-ratio and osmotic resistance, with the mean cell haemoglobin concentration (MCHC) being decreased. Studies on red cell populations of different cell age revealed that the increase of MSA affects younger and older cells, whereas the increase of MCV can mainly be ascribed to young cells with low density. The increased osmotic resistance is mainly determined by older cells due to a more favourable MSA/MCV-ratio. Shortly after splenectomy (n = 5) the MSA of younger and older cells increased, whereas the increase of MCV affected only young cells with a lowered density; moreover, the MSA/MCV-ratio increased in older cells in particular, resulting in a relatively greater increase of osmotic resistance. An impaired maturation of the reticulocyte may underlie the initial increase of MSA and MCV of young cells, but the present results contradict the current view that delayed maturation explains the changes in morphology and osmotic resistance of asplenic red cells.


Subject(s)
Erythrocytes/cytology , Splenectomy , Adult , Aged , Erythrocyte Aging , Erythrocyte Indices , Erythrocytes/metabolism , Female , Humans , Male , Middle Aged , Osmotic Fragility
SELECTION OF CITATIONS
SEARCH DETAIL
...